Clinical trial
Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I…
NCT00022386 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00022386 |
|---|---|
| Title | Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer |
| Official title | An Open-Label Study of PROCRIT (Epoetin Alfa) in Women Undergoing Adjuvant Chemotherapy for Stage I, II, or III Breast Cancer |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Anemia, Breast Cancer, Fatigue |
| Intervention type | Biological, Procedure |
| Interventions | epoetin alfa, quality-of-life assessment |
| Completion | Apr 1, 2004 |
| First posted | Apr 5, 2004 |
| Last update posted | Jul 18, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: